# Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/tocilizumab-for-refractory-rapidly-progressive-interstitial-lung-disease-related/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Xiao Zhang,Shuang Zhou,Chanyuan Wu,Mengtao Li,Qian Wang,Yan Zhao,Xiaofeng Zeng |
| Citations | 47 |
| DOI | 10.1093/rheumatology/keaa906 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3119458569 |
| PMID | 33410494 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Chanyuan Wu](https://scholariq.org/researchers/chanyuan-wu/)

## Paper journal

- [Lara D. Veeken](https://scholariq.org/journals/lara-d-veeken/)

## Paper primary topic

- [Inflammatory Myopathies and Dermatomyositis](https://scholariq.org/topics/inflammatory-myopathies-and-dermatomyositis/)

## Paper topics

- [Inflammatory Myopathies and Dermatomyositis](https://scholariq.org/topics/inflammatory-myopathies-and-dermatomyositis/)
- [Eosinophilic Disorders and Syndromes](https://scholariq.org/topics/eosinophilic-disorders-and-syndromes/)
- [Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis](https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.